Maze Therapeutics, Inc. (MAZE) — Financial ratios
Profitability, liquidity, leverage, and valuation ratios for Maze Therapeutics, Inc., with annual and quarterly history.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Valuation | ||||
| P/E Ratio | -13.58x | 13.37x | -6.95x | -6.07x |
| P/B Ratio | 5.02x | 3.55x | 69.45x | 6.88x |
| P/S Ratio | 0.00x | 4.17x | 0.00x | 0.00x |
| Profitability | ||||
| Gross Margin | 0.0% | 100.0% | 0.0% | 0.0% |
| Operating Margin | 0.0% | 34.4% | 0.0% | 0.0% |
| Net Margin | 0.0% | 31.2% | 0.0% | 0.0% |
| EBITDA Margin | 0.0% | 36.3% | 0.0% | 0.0% |
| Liquidity | ||||
| Current Ratio | 15.50x | 9.76x | 2.09x | 5.11x |
| Quick Ratio | 15.50x | 9.76x | 2.09x | 5.11x |
| Leverage | ||||
| Debt/Equity | 0.07x | 0.14x | 4.94x | 0.32x |
YoY = year-over-year change. Source: FMP..